Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of COPD (according to GOLD guidelines)~* FEV1 \> or equal 30% and \< 50% of predicted normal post-bronchodilator (and at least 0.7 L absolute value)~* COPD symptoms for at least 2 years~* At least 1 exacerbation requiring medical intervention (oral corticosteroid and/or antibiotic treatment and/or need for a visit to an emergency department and/or hospitalization) within 2-12 months before screening~* Current or previous smoker with a cumulative exposure to smoke of more than 20-pack year~Exclusion Criteria:~* Current or past diagnosis of asthma, or any evidence suggestive of asthma~* Positive FEV1 reversibility test~* Clinically significant or unstable concurrent diseases, including clinically significant laboratory abnormalities~* Acute COPD exacerbation or lower tract infection and/or treatment with oral or injectable corticosteroids and antibiotics in the 2 months before screening or during run-in~* Long term oxygen therapy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI (Type: EXPERIMENTAL): None
- Budesonide 200 µg plus formoterol 6 µg DPI (Type: ACTIVE_COMPARATOR): None
- Formoterol 12 µg DPI (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).